Cereno Scientific clarifies information regarding when the warrants of series TO3 are admitted to trading

Cereno Scientific AB (publ) (“Cereno Scientific” or the “Company”) clarifies the information regarding the time of admission to trading of the warrants of series TO3 issued in the Company's rights issue of units, which the board of directors decided on April 20, 2023, with authorization from the annual general meeting on June 1, 2022 (the "Rights Issue"). In the press release on May 26, 2023, about the outcome of the Rights Issue, it was communicated that, in contrast to what was previously communicated, the board of directors decided that the warrants of series TO3 should be taken up for trading in connection with the conversion of BTU into shares of series B and warrants of series TO3, which is estimated to take place during week 23, 2023.

The reason why trading in the warrants of series TO3 begins earlier than previously communicated is that the Company found in a final assessment that the previously brokered trading period cannot likely be considered compatible with good practice on the stock market. Against this background, the board of directors has made the necessary decision to adapt the trading period in accordance with what is now communicated.

Advisers

Mangold Fondkommission AB is financial adviser and MAQS Advokatbyrå AB is legal adviser to Cereno Scientific in connection with the Rights Issue.

For further information, please contact:

Jonas Fogelberg, Interim CFO

Email: info@cerenoscientific.com

http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno Scientific to use their cutting-edge technology CardioMEMS HF System in the study. Cereno Scientific also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno Scientific is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.